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Summary. The study of Streptococcus pneumoniae (the pneumococcus) had
been a central issue in medicine for many decades until the use of antibiotics
became generalized. Many fundamental contributions to the history of microbiol-
ogy should credit this bacterium: the capsular precipitin reaction, the major role
this reaction plays in the development of immunology through the identification of
polysaccharides as antigens, and, mainly, the demonstration, by genetic transfor-
mation, that genes are composed of DNA—the finding from the study of bacteria
that has had the greatest impact on biology. Currently, pneumococcus is the most
common etiologic agent in acute otitis media, sinusitis, and pneumonia requiring
the hospitalization of adults. Moreover, meningitis is the leading cause of death
among children in developing countries. Here I discuss the contributions that led
to the explosion of knowledge about pneumococcus and also report some of the
contributions of our group to the understanding of the molecular basis of three
important virulence factors: lytic enzymes, pneumococcal phages, and the genes
coding for capsular polysaccharides. [Int Microbiol 2006; 9(3):179-190]
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Introduction
Until the 1940s, Streptococcus pneumoniae (the pneumococ-
cus) was a dangerous human killer. In fact, it was the leading
cause of death and was nicknamed “the captain of the knight
of death” because it caused more health problems than car-
diovascular disease and cancer together [70]. In 1944, Avery,
McLeod, and McCarty [5], using the major virulence factor
of pneumococcus (the capsular polysaccharide) as the pheno-
typic marker, were able to demonstrate that genes were made
of DNA. The current importance of this historic bacterium
comes from concern over pneumococcal disease caused by
multidrug-resistant strains. Infectious diseases are the third
leading cause of death in the United States and the leading
cause of morbidity worldwide, with pneumococcus being the
main cause of pneumonia, meningitis, and bloodstream
infections in the elderly, the young, and immuno-compro-
mised individuals [54, 58]. In addition, pneumococcus is the
major cause of middle-ear infections in children. The interest
of many groups of scientists to provide answers to questions
concerning the biology of pneumococcus and its ability to
cause disease is justified by the global importance of S. pneu-
moniae as a cause of illness, sequelae, and death, and
because the spread of drug resistance is undermining our
ability to treat pneumococcal infections [33]. New diagnos-
tic tests and the development of improved vaccines are need-
ed to combat the threat from multiple drug resistance, as is
research on the control of DNA transfer in nature and the
control of capsule production. Existing vaccines have only
limited efficacy, and attempts to combat pneumococcal
infections through a more generalized use of antibiotics
seems unrealistic in the long-term because of the genetic
plasticity of this bacterium, which results in a shift in capsu-
lar type or in the rapid spread of antibiotic-resistant isolates
and the appearance of novel antibiotic resistance ‘determi-
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nants’. Recently, phages and phage products have been pro-
posed as an alternative (or complement) to available antibi-
otics. 
This review provides an updated insight into some
aspects of the historical importance of pneumococcus and its
current clinical importance. It also summarizes current
knowledge regarding the molecular biology of the major gen-
etic traits that play a fundamental role in pneumococcal
microbiology and the development of disease, as well as
strategies to prevent and treat diseases caused by this danger-
ous human pathogen.
From Pasteur and Sternberg (1881) to 1950.
The pneumococcus is a normal component of the microbiota
of the human respiratory tract and a major gram-positive
human pathogen. It has had a long history, one that is inte-
grally connected to the history of several fields of biology,
including microbiology and molecular biology. At the begin-
ning of the twentieth century, pneumococcal pneumonia was
the leading cause of death and, as quoted by Maclyn McCarty
(1911–2005), research directed against this specific medical
problem also resulted in a breakthrough in molecular biology
[46,47]. In 1880, George Sternberg (1838–1915) inoculated
rabbits with his own saliva [61] while Louis Pasteur
(1822–1895) used the saliva of a child that had died from
rabies [59]. Their experiments resulted in the isolation of a
lanceolatus micrococcus, later known as Diplococcus pneu-
moniae. The availability of new biochemical and molecular
techniques for taxonomic identification led to the classifica-
tion of this bacterium within the genus Streptococcus, as
Streptococcus pneumoniae. Sternberg and Pasteur also recog-
nized the presence of a capsule surrounding the diplococcal
form of this microorganism. In 1882, Friedländer identified
the pneumococcus as the major cause of human lobar pneu-
monia [21], and in 1884, Gram developed his now famous
stain technique to facilitate identification of pneumococcus
in histological sections of the lungs [25].
Credit must also be given to the remarkable contribution of
Fred Neufeld (1869–1945) in the identification of characteris-
tics that differentiate pneumococcus from other bacteria. In
1900, he described the bile solubility test [55] and, in 1902, the
Quellung reaction [56]. The bile solubility test is based upon
triggering of the uncontrolled activity of the major pneumo-
coccal lytic enzyme (the amidase LytA) in response to bile
treatment, while Quellung (“swelling” in German) refers to the
refractive property of the pneumococcal capsule when
exposed to homologous antibodies, the so-called capsular pre-
cipitin reaction. Originally, this reaction was erroneously used
to indicate a “swelling” of the capsular polysaccharide that
involved pneumococcus. This technique was introduced in
1931 by Neufeld and R. Etinger-Tulczynska as the preferred
method for typing S. pneumoniae [57]. Interestingly, pneumo-
coccus has also played a historical role in the development of
immunology, when Alphonse R. Dochez (1882–1964) and
Oswald T. Avery (1877–1955) reported that the specific solu-
ble substances of pneumococcus were polysaccharides with
antigenic properties similar to those previously ascribed,
exclusively, to proteins [14].
As cited above, the remarkable clinical importance of
pneumococcus attracted many researchers to study the pecu-
liarities of S. pneumoniae and they became soon aware of the
crucial role played by capsular polysaccharide in the viru-
lence of a given pneumococcal type, of which 90 have been
identified to date [31]. The recognition that loss of capsula-
tion by pneumococcus resulted in a loss of virulence led
Avery and René Dubos (1901–1982) to the isolation of a
bacillus (designated as Bacillus palustris) that produced an
enzyme able to depolymerize the capsular polysaccharide of
pneumococcus type 3 [3,4]. Potential drawbacks to the ther-
apeutic use of this enzyme were the need for a specific
enzyme for each capsular polysaccharide and the fact that,
although effective for rendering the bacteria susceptible to
phagocytosis, the enzyme could not be used to treat lobar
infection.
Austrian concluded that treatment of pneumococcal infec-
tions has followed two, somewhat parallel courses: immu-
notherapy and chemotherapy [2]. The treatment of type 1
pneumococcal pneumonia with type-specific equine anti-
serum was initiated at the Rockefeller Institute in 1913
[3,4,6], where an approximately 50% reduction in mortality
was shown in a mouse model of infection. Simultaneously, in
1911, J. Morgenroth and R. Levy reported the protective
effect in mice of ethylhydrocupreine (optochin), a derivative
of quinine [50]. Assays in vitro soon revealed bacterial resist-
ance to optochin; resistance also occurred in humans, in
whom the drug was briefly used as chemotherapeutic agent .
Later, in the 1930s, sulfapyridine, a sulfonamide, proved to
be moderately successful for treating pneumococcal pneumo-
nia [45]. Capsular serotyping was largely abandoned with the
introduction of penicillin treatment for pneumococcus and
many other bacterial pathogens. In the case of pneumococ-
cus, the overall fatality rate was reduced to 5–8% [2].
In the early 1920s, Frederick Griffith (1877–1941) was
interested in defining the conditions under which unencapsu-
lated variants of pneumococcus type 2 would regain capsula-
tion and virulence in vivo. Using animal models, he observed
that the simultaneous inoculation of mice with live avirulent
bacteria (rough phenotype) and dead smooth virulent strains
resulted in the isolation from dead mice of the smooth pheno-
type. The substance responsible for this unexpected phenotyp-
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ic change was called “the transforming principle” [26]. Avery
and his team took advantage of the natural transformation dis-
played by pneumococcus, namely, the capacity to incorporate
some component from crude extracts of the smooth variant
into the rough strain, to recreate and extend in vitro the obser-
vations made by Griffith (Fig. 1). In those experiments, previ-
ously unencapsulated strains acquired a capsule, becoming, in
McCarty’s words, “sugar-coated bacteria.”
Further studies led to the successful genetic transforma-
tion of S. pneumoniae in vitro. The work of Avery’s group
was accelerated when he was joined by McCarty at his labo-
ratory. McCarty’s special skill as a biochemist to prepare
highly purified DNA by using several pivotal enzymes, i.e.,
DNase and RNase, was fundamental to concluding that genes
were made exclusively of DNA. In other words, DNA was
the “transforming principle”, as reported in the fundamental
paper published in 1944 in The Journal of Experimental
Medicine. No discovery arising from the study of bacteria has
had a greater impact on biology than the finding that genes
consist of DNA [5].
Regrettably, the discovery by Avery, McLeod, and
McCarty was initially received with skepticism by other
researchers and, unfortunately, was not quoted, 9 years later,
in the now-famous paper by Watson and Crick describing the
double-helix model of DNA [68]. During the celebrations
commemorating the 50th anniversary of the proposal of the
DNA double helix, Watson finally honored the fundamental
importance of the discovery by saying: “And the fact that
Avery, McLeod, and McCarty were not awarded the Nobel
Prize is an oversight that, this day, still puzzles” [47]. This
admission should be shouted from the rooftops!
From 1956 to the current state of the art. By
the early 1950s, the wide-spread use of penicillin, the discov-
ery of drugs to combat tuberculosis and, later, the develop-
ment and generalized use of a vaccine against polio had
remarkable effects on the attitudes of scientists and clinicians
towards infections. Stanley Falkow well illustrates this situa-
tion: he recalled that, in the 1960s, several influential scien-
tists suggested to him that studying microorganisms was a
waste of time. One of these mentors, a Nobel laureate, even
went one step further by asking: “Who cares anymore [about
bacteria]?” [60]. Perhaps this complacency about microor-
ganisms reached its highest level when the US Surgeon
General stated that “the war against infectious diseases has
been won”. Instead, as stated in a recent review, microbiolo-
gy “is now at the top of the life science agenda” [17].
These attitudes began to change in the early 1980s, when
products encoded by bacterial genes and plasmids were
found to interfere with the available drugs. At the time,
research on pneumococcus was limited to the few basic sub-
jects that, for more than 20 years, had attracted only a small
number of scientists. From the 1970s until the mid-1980s,
most research on S. pneumoniae focused on the peculiarities
of genetic transformation, including competence develop-
ment (a specialized physiological state that allows the incor-
poration of exogenous DNA), and recombination between
recipient and exogenous DNA. Since then, a variety of exper-
imental approaches, such as tracing the fate of isotopically
labeled DNA, DNA cloning and sequencing, as well as iden-
tification of the surface receptor for competence factor and
donor DNA, have facilitated an understanding of the fascinat-
ing phenomena that lead to transformation in pneumococcus
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Fig. 1. Avery’s historic genetic transformation experiment. An unencapsulated pneumococcal mutant (left) was incubated with purified DNA prepared from
a fully encapsulated type-3 strain. After incubation and recombination, capsulated type-3 transformants were isolated (right).
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[35,64]. The quorum-sensing signal responsible for compe-
tence induction is a heptadecapeptide, called CSP (compe-
tence-stimulating peptide), which derives from a precursor
(comC) following cleavage and transport into the medium by
an ATP-binding cassette transporter, ComAB. This peptide
turned out to be CSP-1, since another peptide with similar
function (CSP-2) was identified later on [29]. More recently,
seven early and 14 late genes involved in genetic transforma-
tion have been identified, the former including genes encod-
ing a two-component regulatory system (ComDE), a histi-
dine kinase, which is also the CSP receptor, and a cognate
regulator. CSP stimuli have also been linked with biofilm for-
mation in Streptococcus species, mainly those forming dental
plaques [63]. It has been suggested that DNA release [52] and
bacterial agglutination properties together with competence
development in S. pneumoniae [30] promote biofilm forma-
tion, thus favoring pneumococcal colonization. In fact, it was
reported that DNA is one of the structural components of the
extracellular matrix of biofilms and is required at early stages
in the process of biofilm formation, as already reported for
other bacteria such as Pseudomonas aeruginosa [69].
Penicillin resistance in pneumococcus is based on a com-
plex mutational pathway that involves multiple alterations in
several penicillin target proteins, the penicillin-binding pro-
teins (PBPs). PBPs are responsible for the last enzymatic
steps leading to formation of the cell wall [8]. In laboratory
mutants, non-PBP genes also contribute to resistance whereas
interspecies gene transfer of PBP variants between commen-
sal streptococci and the pathogen S. pneumoniae appears to
be responsible for the emergence of resistant clones via the
formation of so-called mosaic genes. Pneumococcus strains
that are resistant to many other antibiotics, including
quinolones, have also been described [28].
These findings, together with the persisting morbidity and
mortality associated with pneumococcal infections, led to the
reintroduction of a vaccine program that used a polyvalent
pneumococcal polysaccharide vaccine first tested in the
1960s. Based on the aggregate efficacy of a tetradecavalent
formulation that included the 14 capsular types accounting
for most of the infections in 1977, it was possible to prevent
78.5% of the infections originating from the types included
in the vaccine. In 1983, the formulation of the vaccine was
expanded to 23 capsular polysaccharides, the most complex
vaccine ever administered to humans [2]. A case-controlled
study comprising immunocompetent adults older than age 40
years showed an aggregate protection of about 61% with a
clear decline in protection among those 65 years and older. It
has also been well-documented that polysaccharide vaccines
are suitable antigens for adults but they are not immunogenic
in infants and young children. In the last few years, pneumo-
coccal polysaccharide-protein conjugates, analogous to that
previously developed to combat infections caused by
Hemophilus influenzae type b, have been produced. These
vaccines have proven to be effective in preventing systemic
infection with the capsular types included in the 7-valent
preparation already licensed. However, field trials in humans
are still needed to evaluate the prophylactic potential of these
vaccines.
Contribution of our laboratory to
knowledge of the molecular biology
of the capsule, lytic enzymes, and
bacteriophages of pneumococcus
(1974-2006)
In 1973, I joined the group of Alexander Tomasz at The
Rockefeller University and started to work with pneumococ-
cus. For more than 30 years, my group has focused on three
main aspects of this human pathogen: the lytic enzymes of
the system, the characteristics of the pneumococcal bacterio-
phages, and the molecular analysis of its polysaccharide cap-
sule (for a recent review, see [43]).
Lytic enzymes. Gram-positive bacteria are surrounded
by several peptidoglycan layers (the glycan chain made of
repetitive units of N-acetylglucosamine and N-acetylmuram-
ic acid interlinked by peptide bonds), which give them their
special shape. To allow the cell to expand, this rigid sacculum
must continuously adapt. This cellular restructuring takes
place through the action of murein hydrolases, which are
endogenous enzymes capable of degrading peptidoglycan by
cleaving covalent bonds of the cell wall. Cell-wall hydrolases
(CWH) (or lytic enzymes) have been found in all eubacteria
studied so far, and are thought to play major roles in the biol-
ogy of bacteria, including cellular expansion, division, and
separation of daughter cells. These enzymes are also crucial
in microbial chemotherapy in that they are responsible for the
irreversible effects caused by β-lactam antibiotics.
Pneumococcal and phage lysins hydrolyze specific bonds
in the peptidoglycan network: the N-acetylmuramoyl-L-ala-
nine amide bond between the glycan strand and the cross-link-
ing peptide (NAM)-amidases; [EC 3.5.1.28], or the 1,4-β-link-
age between N-acetylmuramic acid and N-acetyl-D-glu-
cosamine residues of the glycan chain (lysozymes; EC
3.2.1.17) [24,43] (Fig. 2A). Glucosaminidases, transglycosy-
lases, endopeptidases, and phosphorylcholins (PC) esterases
encoded by pneumococcal phages have not been described,
although S. pneumoniae synthesizes a glucosaminidase (LytB)
and a PC esterase (Pce). Lytic transglycosylases differ from
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lysozymes by catalyzing intramolecular transglycosylation of
the glycosyl bond onto the C6 hydroxyl group of the muramic
acid residue, thus forming a 1,6-anhydromuramic acid deriva-
tive. All these enzymes have in common an absolute depend-
ence for activity on the presence of choline in cell-wall tei-
choic acid, the so-called choline-binding proteins (CBPs).
These proteins have a modular organization and one of the
modules consists of motifs that recognize choline (CBD) (see
below). We have taken advantage of the choline analogue
diethylaminoethanol (DEAE) to easily isolate these CBPs on
DEAE-cellulose columns. In this technique, developed some
time ago by our team, CBPs are selectively retained [43].
In addition to S. pneumoniae and its phages, four
prophages from Streptococcus mitis also contain genes encod-
ing CBPs with lytic activity, namely, the NAM-amidases from
EJ-1 (Ejl), SM1 (gp56), φB6 (LytAB6), and φHER (LytAHER)
[24]. Gp56 is very similar (72% identical; 85% similar) to the
Dp-1 NAM-amidase (Pal) whereas Ejl, LytAB6, and LytAHER
are more than 80% identical to the NAM-amidases LytA,
Hbl, MMl, and LytAVO1 encoded by S. pneumoniae and its
temperate phages HB-3, MM1, and VO1, respectively [24].
Although many CBPs with lytic activity have been reported,
note that only six different molecular designs have been
reported so far (Fig. 2B). Four CWHs (LytA, LytB, LytC, and
Pce) have been dissected in detail in pneumococcus. LytA is
the major lytic enzyme and plays a critical role in the biolo-
gy of pneumococcus, as discussed above. Crystal structure
analyses revealed that the pneumococcal C-terminal LytA
domain (C-LytA) displays a solenoid structure made up
exclusively of β-hairpins that pile up to form a left-handed
superhelix [18,19]. Every hairpin corresponds to the motif that
we had defined by analyzing the protein’s primary structure.
For the enzyme to achieve its structure, each choline molecule
must locate in the hydrophobic interphase formed by the con-
PNEUMOCOCCUS
Fig. 2. The cell wall of Streptococcus pneumo-
niae and the pneumococcal and phage cell-
wall hydrolases. (A) Structure of the S. pneu-
moniae peptidoglycan. The different lytic
enzymes are shown in parentheses. Cpl-1 and
Cpl-7 are muramidases (lysozymes; EC
3.2.1.17) from phages Cp-1 and Cp-7, respec-
tively. The (NAM)-amidases Pal, Hbl, Ejl,
Mml, and LytAVO1 are encoded, respectively,
by phages Dp-1, HB-3, EJ-1, MM1, and VO1.
Endopeptidases cleaving bonds other than
those shown in the figure are also possible. TA,
teichoic acid. Solid circles represent PC
residues. (B) Six different molecular architec-
tures of the lytic enzymes of the pneumococcal
system. Sequence similarities among lysins are
indicated by equal shading. Each protein is
identified by its name, number of amino acid
residues (aa), and accession number. Solid,
gray, striped, and cross-hatched bars represent,
respectively, lysozyme (Glyco_hydro_25 fam-
ily; PF01183), amidase_2 (PF01510), ami-
dase_5 (PF05382), and CHAP (PF05257)
domains from the Pfam database. The sub-
strate-binding domains, either a choline-bind-
ing domain (CBD) (PF01473) (open boxes) or
not (PF08230) (stippled boxes), are also
shown. Cpl-7 is a choline-independent lyso-
zyme. Reprinted from FEBS Lett. [39] with
permission of the publisher. In
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secutive hairpins. In addition, the active version of the enzyme
requires the formation of a dimer with a peculiar boomerang
structure. LytC and LytB have similar structural organizations,
in which, unlike LytA, the region for choline recognition is
located at the N-terminal domain, consisting of 11 and 18
repeated motifs, respectively; in contrast to LytA, they also
have signal peptides. Inactivation of the gene lytB leads to the
formation of long cell chains (Fig. 2A) [12].
The first pneumococcal lysozyme described in pneumo-
coccus was LytC. Biologically, it works as an autolysin when
cultures are incubated at 30ºC. As the carrier state of pneu-
mococcus is located in the upper respiratory tract, usually a
well-ventilated region of the body (ca. 34ºC), LytC might
play an important role in the natural transformation process-
es occurring at this location. Likewise, we have observed that
cells lacking this enzyme tend to form clusters.
We have purified LytB, which has been identified as a
glucosaminidase. Purified LytB added to cultures of pneumo-
coccus lytB mutants, which form characteristic long chains,
promoted dispersion of the bacteria into diplococci or short
chains, the typical morphology of wild-type pneumococcal
strains [12]. In addition, the preparation of chimeric enzymes
by means of a translational fusion between gfp, the gene cod-
ing for the green fluorescent protein (GFP), and lytB showed
that LytB accumulates in the cell poles, where it might very
selectively lyse the cell wall. Variations in the composition of
choline motifs might account for the selective recognition of
LytB; for example, there may be specific receptors for this
enzyme at the polar region of the cell surface, where peptido-
glycan hydrolysis would take place. This could explain why
LytB, unlike LytA and LytC, does not behave as an autolytic
enzyme. Since cellular dispersion might be a major factor in
virulence, the lack of LytB might impede pneumococcal dis-
semination during the infective process.
In vitro experiments carried out with purified Pce con-
firmed that this enzyme is a teichoic acid (TA) phosphoryl-
choline esterase able to remove a maximum of only 20% of the
phosphorylcholine residues from cell-wall TA, in agreement
with earlier results [11]. As it is also bound to the envelope, Pce
should play its role only after being secreted through the mem-
brane, although it is currently difficult to assign a defined func-
tion to this enzyme. It has been suggested that the 20% fraction
of residues removable by the enzyme exists either in an
anatomically unique position in the cell wall or represents ter-
minal residues in the TA chains [11,66]. This esterase activity
might regulate the availability of choline residues required for
activity (attachment) of its own and/or of other CBPs. Recently,
a novel choline-binding NAM-amidase (Skl) of S. mitis SK137
containing a CHAP (cysteine, histidine-dependent amidohy-
drolase peptidase) motif has been characterized [39].
Pneumococcal bacteriophages. Bacteriophages are
the most abundant entities in the biosphere (about 1031), and
detailed studies carried out in different bacterial species have
shown that phages can be major vehicles for the transmission
of virulence genes within bacterial populations.
It was not until 1975 that a phage was first isolated in
pneumococcus by two independent groups, phage Dp-1 by C.
Ronda and M. McDonnell at the laboratory of A. Tomasz,
and phage ω1 by G. Tiraby at the laboratory of M. Fox. Six
years later, the Cp (Complutense phage) family was isolated
in our laboratory (for a recent review see [24]). Since then,
we have analyzed a series of lytic and temperate phages. Our
team also showed that the presence of choline in cell-wall
receptors was essential for the adherence of some phages,
including Dp-1. In fact, if choline was replaced by ethanol-
amine, pneumococcal phages could not adsorb and the cell
was resistant to lysis by bacterial or phage-encoded lysins.
More recently, the first complete genomes of two lytic (Dp-1
and EJ-1) and two temperate (MM1 and EJ-1) phages have
been sequenced. We were therefore able to determine the
functional organization of the genome. These clusters con-
tained several genes of great interest that are the focus of our
current research. This is the case for a gene found in the
genome of Dp-1 (orf55, coding for the antireceptor) that
codes for a protein containing motifs similar to those found
in CBPs for the recognition of choline in the cell wall. This
observation explains the requirement of choline by Dp-1
phage receptors for adsorption [24]. Up to now, we have also
described the structural organization of four CBPs identified
as CWHs. These proteins are responsible for the specific
recognition of choline units and are the lytic phage proteins
that liberate progeny from infected S. pneumoniae (Fig. 3). 
The four bacterial lytic enzymes described so far have
great intrinsic flexibility, which enables them to shift recog-
nition units from the C-terminal region to the N-terminal one.
This ability fulfils the exchanging, functional properties that
R.F. Doolittle attributes to a well-defined domain [16]. We
also observed that the murein hydrolase of the Cp-7 phage, a
phage very similar to Cp-1, is an exception to the choline
dependence of phage lytic enzymes, since it is able to
degrade the pneumococcal wall in the absence of this
aminoalcohol. These features are reflected in the enzyme’s
primary structure, because the peculiar motifs for choline
recognition have been replaced by three, identical 48-amino
acid long motifs.
Direct experimental evidence for our hypothesis regarding
the modular organization of enzymes of the pneumococcus sys-
tem was obtained by constructing chimeric functional phage-
bacterial lytic enzymes [13,23]. These showed new functional
characteristics that were the result of exchanges with the
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parental enzymes. We also produced intergeneric chimeric
enzymes with Clostridium acetobutilicum [10]. The results
allowed us to postulate that this kind of exchange could provide
the pneumococcal system with high-plasticity mechanisms to
yield new enzymatic combinations in nature, by means of sim-
ple genetic recombinations that evolution would refine, and
from which pneumococcus would benefit evolutionarily. The
isolation, cloning, and purification of Dp-1 phage lytic enzyme
(Pal) offers an example that supports this working hypothesis.
This enzyme, which we have characterized as an NAM-ami-
dase, has an N-terminal region very similar to that of a lactococ-
cus phage amidase, whereas the C-terminal domain is highly
similar to those able to recognize choline-containing substrates.
Thus, the formation of a natural intergeneric chimera allowed a
primordial enzyme, possibly without a recognition unit, to
obtain such a unit in order to improve its catalytic efficiency.
Since 1927, it has been known that during the lysogenic
state of temperate phages certain genes that code for toxins
are expressed. These toxins are usually the main cause of
bacterial virulence, as is the case, for example, in scarlet
fever. Initial results reported that filtered supernatants of tox-
icogenic streptococcal cultures acquired the ability to pro-
duce scarlatinal toxin, were in fact describing transduction,
the transfer of genetic material to a bacterial cell via phage
infection, even though investigators lacked an explanation
for this phenomenon [67]. Subsequently, their hypothesis,
that bacteria acquire virulence properties from phages, has
been widely accepted. In fact, it has been shown that many
virulence genes are transferred among bacteria by phages
(via transduction) and other mobile genetic elements, such as
plasmids (via conjugation), as well as by incorporation of the
phage genome into the bacterial chromosome. These types of
observations were later extended to cholera and diphtheria;
nowadays the list is abundant [67]. Most probably, this is also
the case in S. pneumoniae. In fact, 70% of the pneumococcal
genomes from clinical isolates contain prophages (or rem-
nants of them). How these phages contribute to pneumococ-
cal virulence is under investigation in our laboratory. We
speculate that the mechanisms of virulence in pneumococcus
follow patterns others than those described thus far.
Since their discovery by d’Hérelle and Twort some 90
years ago, phages have been used as antibacterial therapy in
Eastern Europe [62]. A brilliant experimental variant to
phage therapy was developed recently by Fischetti et al. [42],
in which phage products, i.e., lytic enzymes, were used. In
the case of pneumococcus, these assays included the Pal ami-
dase and the Cpl-1 lysozyme. The lytic enzymes used in this
experimental approach were enzybiotics designed to achieve
cure at the carrier stage in a murine model of pharynx infec-
tion by the administration of instillations of these purified
enzymes. More recently, this experimental approach was
extended to Bacillus anthracis, with the aim of fighting
anthrax, a pathogen that has raised great concern due to the
fear of bioterrorism, and to Streptococcus pyogenes [44]. 
In the case of S. pneumoniae, collaboration between my
team and that from the Instituto de Salud Carlos III, in
Madrid, resulted in a murine septicemia model, in which a
single dose of Cpl-1 lysozyme or Pal amidase was shown to
protect experimental animals from fatal infection by a viru-
lent, clinical pneumococcus. So far, no adverse reactions to
treatment with these murein hydrolases have been observed
[32]. These results are encouraging as a promising new ther-
apeutic approach to lessen the alarming antibiotic resistances
that have evolved in numerous bacterial species, especially
pneumococcus, due to the genetic plasticity of bacteria and to
the misuse of these drugs.
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Fig. 3. The genomes of three pneumococcal bacteriophages, MM1, Dp-1, and Cp-1. Genes are drawn as arrows that indicate the direction of transcription.
White arrows correspond to ORFs that do not have any significant similarity with those included in databases. For MM1, the ends of the genome correspond
to those of the prophage. The putative functions of the gene products correspond to the different types of shading, as indicated at the bottom. Reprinted from
[24] with permission of the publisher.
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Capsular polysaccharide. Pneumococcal capsules are
polysaccharides excreted outside the cell. They are usually
composed of repeating units of simple sugars that remain
attached, probably in a covalent form, to the outer surface of
the bacterium. Capsules are usually associated with increased
virulence as they may function as adhesins, recognition mol-
ecules, and/or by favoring the camouflage of the parasite
against the host immune response. The capsule of polysaccha-
ride that completely envelops S. pneumoniae acts as a protec-
tive layer that isolates the bacterial cell from the environment.
A remarkable combination of a series of genes at the cap-
sular cluster results in at least 90 structurally and serologically
distinct capsular polysaccharides (serotypes) that contribute to
the clinical importance of S. pneumoniae. Although the bio-
chemistry of some serotypes has been known for a long time,
it was not until the early 1990s that the molecular bases of cap-
sule formation in several bacteria species began to be under-
stood. In 1993, my group reported the location and isolation of
a gene coding for serotype-3 capsule [22]. Since the late 1950s,
it had been known that genes coding for the pneumococcal
capsule formed a cluster (Fig. 4). The localization and isolation
of those genes (cap/cps) showed, as biochemists had suggest-
ed, that the greater the complexity of the capsule’s composi-
tion, the more genes involved in its formation. This proposal
was fully confirmed upon molecular analysis.
According to the most recent data, there are three differ-
ent organizational models of the capsular gene cluster in S.
pneumoniae (for a review, see [38]):
(i) The most common capsular gene cluster organization
corresponds to that of types 1, 2, 4, 6B, 8, 9V, 14, 18C, 19F,
19A, 19B, 19C, 23F, and 33F. Moreover, sequencing of the
genes encoding the already-known 90 pneumococcal
serotypes [31] is currently underway at the Sanger Institute
[http://www.sanger.ac.uk/Projects/S_pneumoniae/CPS].
Most of the gene clusters share a similar organization. The
cap/cps gene cluster is located between dexB and aliA, two
genes that do not participate in capsular biosynthesis (Fig. 4).
In all cases, a functional promoter is located immediately
upstream of the gene cluster [1,40,53], and the first four open
reading frames (ORFs) of the cap/cps operon are well-con-
served among serotypes, although only the first ORF is virtu-
ally identical in all of the types analyzed so far. In spite of the
sequence conservation of the two first ORFs among
serotypes, these genes show enough polymorphism to allow
the serotyping of S. pneumoniae isolates by PCR-based meth-
ods [34,36,48]. In this model of capsular clusters, the mecha-
nisms of regulation and transport of capsular polysaccharide
(CP) have been recently studied. Production of most CPs is
achieved through the formation of a lipid-linked repeat unit
that is synthesized on the intracellular face of the membrane,
exported to the surface, and polymerized. It has been reported
that deletion of either cps2A, 2B, 2C, or 2D genes in the
serotype 2 gene cluster does not affect the transfer of CP to the
cell wall [7]. Interestingly, the correlation between tyrosine
phosphorylation of CpsD and CP production is a matter of
current debate. It was first reported that CpsD acts as a nega-
tive regulator of capsule biosynthesis [51].
(ii) Type 3 is an exceptional gene cluster in that the four
initial ORFs of the capsular operon are not involved in CP
biosynthesis and are not expressed [1] (Fig. 4). A functional
promoter is located immediately upstream of the first gene of
the operon (cap3A). In accordance with the simple chemical
structure of the type 3 repeating unit [cellobiuronic acid units
connected in a β(1→3) linkage], only three complete genes
were found in the capsular operon (Fig. 4). Moreover, the
third gene (cap3C; also referred to as cps3U), is not required
for CP biosynthesis since the biochemical function of its
product (a UDP-Glc pyrophosphorylase) is compensated by
that of the galU gene, located far away in the S. pneumoniae
chromosome [49]. The GalU enzyme has been shown to be
essential for CP synthesis and is required for the interconver-
sion of UDP-Glc and UDP-galactose by way of the Leloir
pathway [20]. Prokaryotic UDP-Glc pyrophosphorylases are
well-conserved and, although UDP-Glc pyrophosphorylases
are also present in eukaryotes, these enzymes are completely
unrelated to their prokaryotic counterparts ([49] and refer-
ences therein).
(iii) The most peculiar case among pneumococcal capsu-
lar genes is provided by type 37 isolates. These strains are
genetically binary; that is, they contain a cap37 locus virtual-
ly identical to that of type 33F strains [40,41] but several
mutations have inactivated some of the ORFs and, conse-
quently, this locus is actually silent. It was also demonstrated
that type 37 capsulation is due to the presence of a single
copy of a gene (tts) located far apart from the cap cluster
(Fig. 4). The Tts synthase contains several motifs known to
be characteristic of cellulose synthases and other glucosyl-
transferases [37].
In a bacterium with natural genetic transformation, the
modular structure of the pneumococcal capsule facilitates the
exchange of specific genes between serotypes by means of
recombination between flanking homologous regions. This
exchange, evidenced by Coffey et al. [9], is of great clinical
importance, particularly when it occurs between antibiotic-
resistant strains. In fact, this implies an epidemiological chal-
lenge in controlling the universal expansion of some pneu-
mococcal strains. In addition, the fact that changes in capsu-
lar type by recombination might be relatively frequent among
pneumococci will impact the long-term efficacy of conjugate
pneumococcal vaccines, which will protect only against a
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limited number of serotypes [65]. Besides the general mech-
anism that controls capsule formation, transposition-like
events may contribute to capsular diversity in S. pneumoniae,
as evidenced by the fact that all the capsular gene clusters of
S. pneumoniae are flanked by insertion sequence elements.
Sequencing of the galU locus has provided insight into a
gene implicated in the synthesis of all known pneumococcal
serotypes. GalUprotein is thus an ideal metabolic target for
future clinical approaches that would involve blocking cap-
sule formation by S. pneumoniae. It is indeed an interesting
candidate for the design of a conjugate vaccine.
Future prospects
The global importance of S. pneumoniae as the cause of ill-
ness, adverse sequelae, and death, as well as the emergence
of drug resistance that is making these infections more diffi-
cult to treat, justify the current interest of many research
teams in this major human pathogen. Gene flow in natural
populations needs to be further examined to understand the
continuous evolution of multiple antibiotic resistances. The
role of vectors, including conjugative transposons and bacte-
riophage, needs to be addressed in a clinical setting. The
potential emergence of new pathogens from related oral
microbiota needs to be examined through better characteriza-
tion of these organisms as donors of genetic material to the
pneumococcal gene pool and as organisms that could emerge
within the pneumococcal nasopharyngeal habitat. Me-
chanisms and environmental stresses promoting genetic
transformation and mutational events among pneumococci
and between pneumococci and the related oral microbiota
also deserve further study.
There is also the problem of the poor efficacy of vaccines
PNEUMOCOCCUS
Fig. 4. Genetic organization of the S. pneumoniae region containing the cap/cps gene cluster of three representative capsular types. Large
and thin arrows represent complete or interrupted ORFs, respectively. Regions showing more than 90% identical nucleotides are represent-
ed by identical color and shading. The ‘inverted matchsticks’ represent putative transcription terminators. Bent arrows show the location of
functional promoters. The composition of the monomeric unit of the capsular polysaccharide (CP) encoded by the three represented
serotypes is also shown. Black lines surround the genes of the capsular cluster coding for these polysaccharides. The inactive cap37 (=
cap33f) cluster present in type 37 pneumococci is also shown. Reprinted from FEMS Microbiol. Rev. with permission of the publisher.
[López, García (2004) FEMS Microbiol. Rev. 28:553-580]
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due to the well-documented genetic plasticity of S. pneumo-
niae. In addition, eradication of pneumococcus through the
generalized use of antibiotics looks to be unrealistic, again
because of the bacterium’s genetic plasticity, which results in
the rapid appearance and spreading of antibiotic-resistant iso-
lates and antibiotic resistance “determinants”. Moreover,
because S. pneumoniae is a human commensal, it may not be
sound to disturb the normal flora, with unpredictable long-
term consequences. Finally, it is widely recognized that
biofilm formation is the natural form of growth for most
microbial species in their natural habitats [27]. A biofilm is a
highly structured sessile microbial community characterized
by bacterial cells attached to a surface or interface and embed-
ded in a matrix of extracellular polymeric substances [15]. To
ascertain whether S. pneumoniae benefits from forming an
interactive community and whether this sessile mode of
growth is the result of random accretion of bacterial cells or
of a community of bacteria cooperating to form a well-
defined structure, we studied the structural peculiarities of
these biological entities by using laboratory conditions that
favor biofilm formation. Our results provided evidence that
pneumococci form biofilms on abiotic surfaces. Furthermore,
we studied conditions that lead to defective biofilm develop-
ment by using genetic approaches focused on the earliest
stage of biofilm accretion, that is, the surface attachment of S.
pneumoniae, before an ordered three-dimensional structure is
constructed. Our analyses revealed the role of certain gene
products in primary attachment during biofilm formation and
suggested that DNA and several proteins contribute to the for-
mation of extracellular matrix in this system. These experi-
mental data are important steps in furthering our understand-
ing of the putative role of biofilms in some stages of pneumo-
coccal infection and their possible contribution to increasing
antibiotic resistance in the clinical setting.
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Pneumococcus: la bacteria recubierta de azúcar
Resumen. Hasta el empleo generalizado de los antibióticos, el estudio de
Streptococcus pneumoniae (el neumococo) fue un tema central en medicina
durante muchas décadas. Muchas contribuciones fundamentales de la histo-
ria de la microbiología se deben a esta bacteria: la reacción capsular de la
precipitina, su destacado papel en el desarrollo de la inmunología mediante
la identificación de polisacáridos como antígenos, y, principalmente, la
demostración, por transformación genética, de que los genes están compues-
tos de DNA, que supuso el mayor impacto en biología a partir del estudio de
las bacterias. Actualmente, el neumococo es el agente etiológico más fre-
cuente en procesos de infección aguda del oído medio, sinusitis y neumonía
que requieren hospitalización en adultos. Además, la meningitis es una de las
principales causas de muerte en los niños de países en vías de desarrollo.
Esta revisión trata las contribuciones que han llevado a un elevado nivel de
conocimiento sobre el neumococo y describe algunas contribuciones de
nuestro grupo al conocimiento de la base molecular de los tres factores prin-
cipales de la virulencia, es decir, las enzimas líticas, los fagos y los genes que
codifican los polisacáridos capsulares. [Int Microbiol 2006; 9(3):179-190]
Palabras clave: Streptococcus pneumoniae · polisacárido capsular ·
hidrolasas de pared celular · bacteriófagos · factores de virulencia
Pneumococcus: a bactéria recoberta por açúcar
Resumo. Até o emprego generalizado dos antibióticos, o estudo de
Streptococcus pneumoniae (o neumococo) foi um tema central em medicina
durante muitas décadas. São numerosas as contribuições fundamentais na
história da microbiologia devidas a esta bactéria: a reação capsular da preci-
pitina, seu papel no desenvolvimento da imunologia através da identificação
de polissacarídeos como antígenos, e, principalmente, a demonstração, pe
transformação genética,  que os genes são compostos por DNA,  o que repre-
sentou o maior impacto em biologia a partir do estudo das bactérias. Atual-
mente, o neumococo é o agente etiológico mais comum em processos de
otite aguda, sinusites e pneumonia que requerem hospitalização em adultos.
No entanto, é a meningite a causa principal de morte em países desenvol-
vidos e em crianças em países em vias de desenvolvimento. Nesta revisão,
propomos também uma análise das contribuições que levaram ao elevado
nível de conhecimento sobre o neumococo, assim como um breve relatório
sobre as contribuições de nosso grupo à base molecular dos três principais
fatores de virulência isto é, os enzimas líticos, os fagos os genes que codifi-
cam os polissacarídeos capsulares. [Int Microbiol 2006; 9(3):179-190]
Palavras chave: Streptococcus pneumoniae · polissacarídeos capsular ·
hidrolases de parede cellulare · bacteriófago · fatores de virulência
